Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in the Netherlands / NCT07792317
Recruiting Not applicable

Hypothermic Machine Perfusion With Omnisol of Deceased Donor Kidneys Prior to Transplantation

NCT07792317 · tracked via the Priya Life Science Netherlands tracker
Sponsor
Vivalyx GmbH
Phase
Not applicable
Started
2025-11-17
Last updated
2026-08-28

Condition(s) studied

Kidney TransplantKidney FailureRenal and Urinary Tract Therapeutic ProceduresEnd Stage Renal Disease (ESRD)

Investigational drug(s) / intervention(s)

Omnisol organ preservation solution

Omnisol organ preservation solution: Omnisol for HMP of deceased donor kidneys

Study summary

Insufficient availability of organs from brain dead (DBD) and living donors has necessitated increased use of less than optimal organs from donation after cardiac death (DCD) or from extended criteria donors. Preservation of DCD organs using the current clinically applied preservation solutions is associated with up to 73% incidence of delayed graft function, highlighting the need for new preservation solutions designed to improve early graft function.

Omnisol is expected to result in equivalent or improved kidney preservation as compared to currently marketed organ preservation solutions used for HMP.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion for donor: * Donor age \> 18 years * Brain Death (DBD) or Circulatory Death \< 50 years (DCD\<50) * Accepted for transplantation according to local criteria Inclusion for recipient: * Male or female, age \> 18 years * Able and willing to comply with all study requirements (in opinion of investigator or deputy) * General inclusion criteria applicable to kidney transplantation: * Listed for renal transplantation due to end stage renal disease on the Eurotransplant (ET) list * Fit to proceed with kidney transplantation (in opinion of investigator or deputy) Exclusion for donor: * Donor kidneys accepted as a pair for dual transplant * Circulatory Death ≥ 50 years (DCD 50+) * Participation in an investigational study likely to affect interpretation of the trial data Exclusion for recipient: * General exclusion criteria applicable to kidney transplantation * Breast-feeding or pregnant, as confirmed by pregnancy test or blood test, or plans to become pregnant over the study period * Participation in an investigational study likely to affect interpretation of the trial data * Mental disabilities that may affect the understanding of the study requirements including the ability to adhere to medication regime (in opinion of investigator or deputy) * Undergoing living donor kidney transplantation * Undergoing dual kidney transplantation * Undergoing transplantation of other organ(s) in addition to the kidney * Highly immunized patients with vPRA \> 85% (as confirmed by routine cross-matching test) * Other substantial risk of transplant not proceeding (in opinion of investigator or deputy) * Other significant disease or disorder which, in the opinion of the Investigator, may: (i) put the participant at risk by participating in the study; (ii) influence the result of the study; (iii) affect the participant's ability to participate in the study

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Erasmus Medical Center Rotterdam Netherlands Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07792317 on ClinicalTrials.gov ↗ ← All trials in the Netherlands